Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Bausch Health Companies Inc.    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
10/14/2020 10/15/2020 10/16/2020 10/19/2020 10/20/2020 Date
22.02(c) 22.94(c) 22.59(c) 22.73(c) 22.33(c) Last
917 491 537 096 434 599 1 441 334 1 440 978 Volume
-0.45% +4.18% -1.53% +0.62% -1.76% Change
More quotes
Financials (USD)
Sales 2020 7 837 M - -
Net income 2020 -622 M - -
Net Debt 2020 22 314 M - -
P/E ratio 2020 -10,1x
Yield 2020 -
Sales 2021 8 482 M - -
Net income 2021 -84,5 M - -
Net Debt 2021 20 922 M - -
P/E ratio 2021 -195x
Yield 2021 -
Capitalization 6 108 M 6 108 M -
EV / Sales 2020 3,63x
EV / Sales 2021 3,19x
Nbr of Employees 21 700
Free-Float 98,0%
More Financials
Company
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic... 
Sector
Pharmaceuticals
Calendar
11/03Earnings Release
More about the company
Notations Surperformance© of Bausch Health Companies Inc.
Trading Rating : Investor Rating :
More Ratings
All news about BAUSCH HEALTH COMPANIES INC.
06:56aBAUSCH HEALTH : Emerade™ (epinephrine 0.3 mg and 0.5 mg) now available in ..
AQ
10/16BAUSCH HEALTH : and BHVI Announce Exclusive Global Licensing Agreement for Myopi..
AQ
10/15BAUSCH HEALTH : And BHVI Announce Exclusive Global Licensing Agreement For Myopi..
AQ
10/15BAUSCH HEALTH : And BHVI Announce Exclusive Global Licensing Agreement For Myopi..
PR
10/13BAUSCH HEALTH : Licenses Eyenovia's Investigational Treatment for The Reduction ..
AQ
10/13BAUSCH HEALTH : Eyenovia to Host Investor Call to Discuss Recent Licensing Agree..
AQ
10/12EYENOVIA : Bausch Health Licenses Eyenovia's Investigational Treatment For The R..
AQ
10/09BAUSCH HEALTH COMPANIES INC : . - Salix to Present Clinical Data at United Europ..
AQ
10/09BAUSCH HEALTH COMPANIES INC : . Provides Preliminary Update on Third-Quarter 202..
AQ
10/08TSX gains on energy boost
RE
10/08BAUSCH HEALTH : Salix To Present Clinical Data At United European Gastroenterolo..
AQ
10/08BAUSCH HEALTH : Salix To Present Clinical Data At United European Gastroenterolo..
PR
10/08BAUSCH HEALTH COMPANIES INC. : Results of Operations and Financial Condition (fo..
AQ
10/08BAUSCH HEALTH COMPANIES INC : . Provides Preliminary Update On Third-Quarter 202..
AQ
10/08BAUSCH HEALTH COMPANIES INC. : Provides Preliminary Update On Third-Quarter 2020..
PR
More news
News in other languages on BAUSCH HEALTH COMPANIES INC.
02/14BAUSCH HEALTH COMPANIES INC. : Veröffentlichung des Jahresergebnisses
02/14BAUSCH HEALTH COMPANIES INC. : publication des résultats annuels
01/11Behält Warren Buffett am Ende doch recht?
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre lundi à Wall Street
2019WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street (actualisé)
More news
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 26,33 $
Last Close Price 17,21 $
Spread / Highest target 191%
Spread / Average Target 53,0%
Spread / Lowest Target -1,22%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
David Robert Hale Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC.-41.52%6 108
JOHNSON & JOHNSON-1.06%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-3.14%210 050
MERCK & CO., INC.-13.50%198 975
NOVARTIS AG-14.48%190 349